📊 EKSO Key Takeaways
Is Ekso Bionics Holdings, Inc.. (EKSO) a Good Investment?
Ekso Bionics faces severe operational challenges with negative operating and net margins exceeding -100%, deteriorating revenue (-28.6% YoY), and massive cash burn (-$12M FCF) that threatens sustainability. Despite maintaining adequate liquidity ratios, the company's inability to generate positive operating cash flow, combined with persistent losses and negative ROE/ROA, indicates fundamental business model distress requiring immediate operational restructuring.
Ekso Bionics' fundamentals are weak: revenue declined 28.6% year over year while operating losses remained larger than sales, producing deeply negative operating and net margins. Although gross margin is still respectable and leverage is not extreme, the combination of heavy cash burn, very limited cash on hand, and negative returns on assets and equity points to poor growth quality and meaningful financing risk unless the business materially improves commercialization and cost structure.
Why Buy Ekso Bionics Holdings, Inc.. Stock? EKSO Key Strengths
- Solid gross margin of 53.5% demonstrates pricing power and product viability at unit economics level
- Current ratio of 1.63x and quick ratio of 1.07x provide adequate short-term liquidity cushion
- Conservative leverage with debt-to-equity of 0.22x limits financial distress risk in near term
- Gross margin of 53.5% suggests the core product economics can support profitability if scale improves
- Current ratio of 1.63x and quick ratio of 1.07x indicate near-term liquidity is not yet distressed
- Debt/equity of 0.22x keeps balance-sheet leverage relatively modest
EKSO Stock Risks: Ekso Bionics Holdings, Inc.. Investment Risks
- Revenue contraction of 28.6% YoY indicates severe demand weakness or market share loss requiring immediate strategic intervention
- Operating cash flow of -$11.8M with negative FCF margin of -93.7% at current burn rate exhausts $1.2M cash reserves in 1-2 months without financing
- Deeply negative profitability metrics (operating margin -104.1%, net margin -91.4%, ROE -129.6%) signal unsustainable business operations and value destruction
- Heavy net losses of -$11.7M on only $12.8M revenue indicates severe cost structure misalignment and operational inefficiency
- Revenue contraction of 28.6% signals weak demand traction or execution issues
- Operating margin of -104.1% and free cash flow of -$11.99M show the business is consuming cash at an unsustainable rate
- Cash balance of only $1.17M versus annual operating cash outflow of $11.80M raises a high risk of future capital needs
Key Metrics to Watch
- Quarterly revenue trend - stabilization or continued decline signals market viability
- Operating cash flow - path to positive OCF is critical for survival without continuous financing
- Cash burn rate and runway - days of cash available given current cash consumption patterns
- Gross margin sustainability - any decline below 50% would further deteriorate fundamental value
- Product adoption and pipeline - evidence of new customer wins to support revenue recovery
- Quarterly revenue growth and order conversion to confirm demand recovery
- Operating cash burn relative to cash balance, including any improvement in operating margin
Ekso Bionics Holdings, Inc.. (EKSO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Ekso Bionics Holdings, Inc.. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
EKSO Profit Margin, ROE & Profitability Analysis
EKSO vs Industrial Sector: How Ekso Bionics Holdings, Inc.. Compares
How Ekso Bionics Holdings, Inc.. compares to Industrial sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Ekso Bionics Holdings, Inc.. Stock Overvalued? EKSO Valuation Analysis 2026
Based on fundamental analysis, Ekso Bionics Holdings, Inc.. has mixed fundamental signals relative to the Industrial sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Ekso Bionics Holdings, Inc.. Balance Sheet: EKSO Debt, Cash & Liquidity
EKSO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Ekso Bionics Holdings, Inc..'s revenue has grown significantly by 59% over the 5-year period, indicating strong business expansion. The most recent EPS of $-8.43 indicates the company is currently unprofitable.
EKSO Revenue Growth, EPS Growth & YoY Performance
EKSO Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $4.1M | -$1.4M | $-0.54 |
| Q2 2025 | $2.1M | -$2.4M | $-1.24 |
| Q1 2025 | $3.4M | -$2.9M | $-0.12 |
| Q3 2024 | $4.1M | -$2.1M | $-0.10 |
| Q2 2024 | $4.7M | -$2.4M | $-0.13 |
| Q1 2024 | $3.8M | -$3.4M | $-0.20 |
| Q3 2023 | $3.3M | -$3.0M | $-0.24 |
| Q2 2023 | $3.5M | -$3.0M | $-0.23 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Ekso Bionics Holdings, Inc.. Dividends, Buybacks & Capital Allocation
EKSO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Ekso Bionics Holdings, Inc.. (CIK: 0001549084)
📋 Recent SEC Filings
❓ Frequently Asked Questions about EKSO
What is the AI rating for EKSO?
Ekso Bionics Holdings, Inc.. (EKSO) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 92% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are EKSO's key strengths?
Claude: Solid gross margin of 53.5% demonstrates pricing power and product viability at unit economics level. Current ratio of 1.63x and quick ratio of 1.07x provide adequate short-term liquidity cushion. ChatGPT: Gross margin of 53.5% suggests the core product economics can support profitability if scale improves. Current ratio of 1.63x and quick ratio of 1.07x indicate near-term liquidity is not yet distressed.
What are the risks of investing in EKSO?
Claude: Revenue contraction of 28.6% YoY indicates severe demand weakness or market share loss requiring immediate strategic intervention. Operating cash flow of -$11.8M with negative FCF margin of -93.7% at current burn rate exhausts $1.2M cash reserves in 1-2 months without financing. ChatGPT: Revenue contraction of 28.6% signals weak demand traction or execution issues. Operating margin of -104.1% and free cash flow of -$11.99M show the business is consuming cash at an unsustainable rate.
What is EKSO's revenue and growth?
Ekso Bionics Holdings, Inc.. reported revenue of $12.8M.
Does EKSO pay dividends?
Ekso Bionics Holdings, Inc.. does not currently pay dividends.
Where can I find EKSO SEC filings?
Official SEC filings for Ekso Bionics Holdings, Inc.. (CIK: 0001549084) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is EKSO's EPS?
Ekso Bionics Holdings, Inc.. has a diluted EPS of $-4.91.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is EKSO a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Ekso Bionics Holdings, Inc.. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is EKSO stock overvalued or undervalued?
Valuation metrics for EKSO: ROE of -129.6% (sector avg: 15%), net margin of -91.4% (sector avg: 10%). Compare these metrics with sector averages to assess valuation.
Should I buy EKSO stock in 2026?
Our dual AI analysis gives Ekso Bionics Holdings, Inc.. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is EKSO's free cash flow?
Ekso Bionics Holdings, Inc..'s operating cash flow is $-11.8M, with capital expenditures of $188.0K. FCF margin is -93.7%.
How does EKSO compare to other Industrial stocks?
Vs Industrial sector averages: Net margin -91.4% (avg: 10%), ROE -129.6% (avg: 15%), current ratio 1.63 (avg: 1.8).